CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
SLI-F06 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03880058
NCT03880058Phase 2Completed
CompareCT.gov

Safety and Efficacy of SLI-F06 in Wound Healing and Scar Appearance in Pre-Abdominoplasty Surgical Excisions and Post-Operative Scar Appearance In Subjects Undergoing Abdominoplasty

Scarless Laboratories, Inc.·interventional·Posted Mar 19, 2019·Updated Apr 18, 2023

In Brief

A Phase 2 clinical trial evaluating SLI-F06 and Formulation buffer for Scars. Completed, enrolled 22 participants across 3 sites.

Detailed Summary

Multicenter, double-blind study comparing SLI-F06 to vehicle formulation buffer for the improvement in scar appearance and wound strength in routine surgical excisions, as well as post-operative abdominoplasty scar appearance.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsScars
CountriesUnited States
Collaboratorsethica Clinical Research Inc.

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMar 19, 2019
Enrollment StartMar 3, 2019
Primary CompletionMay 18, 2021
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 7.3 years ago

Interventions

SLI-F06drug

Active treatment

Formulation bufferdrug

Placebo treatment